Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Long-term disease-free survival effected by gemcitabine in a heavily pretreated patient with recurrent ovarian carcinoma.

Piura B

Unit of Gynecologic Oncology, Department of Obstetrics and Gynecology, Soroka Medical Center and Faculty of Health Sciences, Cancer Research Center, Ben-Gurion University of the Negev, PO Box 151, Beer-Sheva, 84101, Israel. piura@bgumail.bgu.ac.il

INTRODUCTION: Gemcitabine has been shown to have modest activity and low and well-tolerated toxicity in heavily pretreated patients with recurrent ovarian carcinoma. CASE REPORT: A 46-year-old patient with recurrent ovarian carcinoma who failed with two previous lines of chemotherapy has for the last 40 months received third-line chemotherapy with gemcitabine. This has resulted in an extraordinary long-term disease-free survival of 38 months. Toxicity has been low and well tolerated. CONCLUSION: Gemcitabine seems to be an attractive agent for salvage chemotherapy in ovarian carcinoma patients who failed with prior lines of chemotherapy.

Published 7 March 2005 in Arch Gynecol Obstet, 271(2): 182-3.
Full-text of this article is available online (may require subscription).

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.